The NY Times reports in a recent article that Diabetes drugs must face tougher safety standards that protect patients from heart risks associated with these drugs. The FDA has voted 14-2 to prolong trial study time to assure that diabetic drugs do not carry risks of heart problems.
This concern on diabetic drugs came about shortly after the FDA was criticized for handling the release of the GlaxoSmithKline pill. The drug was released in 1999, but only last November was a warning issued about potential heart risks. The problem lies in the testing phase; it takes nearly five to seven years to complete. Studies should begin way before drugs are submitted to the FDA, and finished shortly after its release.
No comments:
Post a Comment